–EffePharm Announces Self-GRAS for Its New NAD+ Booster, UthPeak™ NMNH–
SHANGHAI, China, Sept. 05, 2024 – EffePharm has announced that its proprietary UthPeak™ NMNH (reduced NMN) has achieved self-affirmed GRAS (generally recognized as safe) status following a recent review by an independent panel of qualified scientific and toxicology experts.
In accordance with Food and Drug Administration (FDA) requirements, the panel agreed that the data demonstrate UthPeak™ NMNH can be sold, used, and consumed in the U.S. food supply.
UthPeak™, marketed as "The Next-Gen Super NAD+ Enhancer," is a patent-pending crystalline NMNH that has demonstrated a remarkable 10X surge in NAD+ levels. UthPeak™ is believed to be the first NMNH brand to receive self-affirmed GRAS as a new generation NAD+ precursor.
"The self-affirmed GRAS status is a testament to the safety and innovation of UthPeak™ NMNH and marks an essential step on our path toward commercialization," said Dr. Jianjun YU, EffePharm’s R&D Director. "At EffePharm, our business philosophy is rooted in delivering unique market value backed by scientific evidence. From our patent-protected crystalline form to extensive clinical studies, we believe UthPeak™ NMNH will provide distinct competitive advantages, enriching our clients' product offerings and enhancing their brand value."
UthPeak™ Preclinical and Clinical Study
UthPeak™ has undergone rigorous toxicology and efficacy tests in animals, revealing its potential benefits in anti-aging, anti-fatigue, sleep quality improvement, brain function enhancement, and cardiovascular health promotion. EffePharm is currently conducting human clinical trials to further validate the safety of UthPeak™ NMNH in humans. These trials are anticipated to conclude by the end of 2024.
UthPeak™ NMNH stands apart from other NAD+ boosters available on the market. Its unique structure allows for a higher conversion rate to NAD+, resulting in elevated intracellular levels of this crucial molecule. However, due to its structural properties, NMNH is highly unstable, making it significantly more challenging to create long shelf-life products compared to NMN and NR. With a dedicated focus on premium anti-aging ingredients, EffePharm's UthPeak™ has tackled these challenges, which, along with its GRAS designation, highlight the company's industry leadership in the transition to a more potent NAD+ future.
To learn more about UthPeak™ NMNH visit www.uthpeak.com.
About EffePharm:
Founded in 2017, EffePharm is a biotechnology company specializing in providing advanced wellness solutions to its global users. EffePharm is founded on the belief that everyone should have equal access to health and nutrition. EffePharm advocates for innovative bioscience applications, increased accessibility of nutrition, and improved quality of life. Committed to delivering efficacy-verified products to the market, EffePharm has established a portfolio of over 600 business partners worldwide, benefiting millions of consumers to thrive throughout their health and nutrition journeys.
Comments